225 mg BNC210

DRUG2 trials

Sponsors

Bionomics Limited

Conditions

Social Anxiety Disorder

Phase 2

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

CompletedNCT05193409

Bionomics LimitedSocial Anxiety Disorder

Start: 2022-02-02End: 2022-10-17Updated: 2025-03-18

Phase 3

Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1

CompletedNCT06510504

Bionomics LimitedSocial Anxiety Disorder

Start: 2024-08-06End: 2025-09-19Updated: 2026-05-19

Related Papers

A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) – The PREVAIL study

Psychiatry Research2025-02-104 citations